Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)

NCT ID: NCT05388760

Last Updated: 2026-01-26

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-09-07
• Study Completion Date: 2026-04-23

Brief Summary

The main purpose of this trial is to investigate what happens to the trial drug in the body and to confirm that it is safe to use and effective for treating atopic dermatitis (AD) in children.

The trial will last up to maximum of approximately 194 weeks, and there will be up to 59 visits. The visits will be held approximately every second week for the first 68 weeks, then the visits will be held every six weeks for the rest of the treatment period. From week 26, every second visit will be held by phone and every second visit will be held on site.

The first part of the trial is called a screening period and will last between 2 and 6 weeks. After the screening period, the trial drug will be administered to the child by subcutaneous (SC) injection. The treatment period with tralokinumab is divided in 3 parts: 1.) initial treatment period for 16 weeks, 2.) open-label treatment period for 52 weeks and 3.) long-term extension treatment period for up to 106 weeks followed by a 14-week safety follow-up period.

All children will use an emollient twice daily (or more) for at least 14 days prior to start of treatment and will continue this treatment throughout the trial. If medically necessary, rescue treatment for AD is allowed at the discretion of the trial doctor.

Conditions

Atopic Dermatitis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Cohort 1 (6 to <12 years) - tralokinumab dose regimen A

Group Type: EXPERIMENTAL

Tralokinumab

Intervention Type: DRUG

A loading dose under the skin (s.c.) at first treatment visit and then injections in accordance with a pre-defined schedule for 16 weeks (initial treatment) followed by a maintenance treatment for 52 weeks (open-label treatment) and a long-term extension treatment period for up to 106 weeks.

Cohort 1 (6 to <12 years) - tralokinumab dose regimen B

Group Type: EXPERIMENTAL

Tralokinumab

Intervention Type: DRUG

A loading dose under the skin (s.c.) at first treatment visit and then injections in accordance with a pre-defined schedule for 16 weeks (initial treatment) followed by a maintenance treatment for 52 weeks (open-label treatment) and a long-term extension treatment period for up to 106 weeks.

Interventions

Tralokinumab

A loading dose under the skin (s.c.) at first treatment visit and then injections in accordance with a pre-defined schedule for 16 weeks (initial treatment) followed by a maintenance treatment for 52 weeks (open-label treatment) and a long-term extension treatment period for up to 106 weeks.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Diagnosis of AD (as defined by Hanifin and Rajka criteria for AD).
• Age 6 to <12 years at time of the baseline visit.
• Body weight at baseline of ≥17 kg.
• History of AD for ≥ 12 months at screening.
• History of TCS and/or TCI treatment failure (due to inadequate response or intolerance) or subjects for whom these topical AD treatments are medically inadvisable.
• AD involvement of ≥10% body surface area at screening and baseline.
• An EASI score of ≥16 at screening and at baseline.
• An Investigator's Global Assessment (IGA) score of ≥3 at screening and at baseline.
• Emollient twice daily (or more) for at least 14 days prior to baseline.

Exclusion Criteria

• Active dermatologic conditions that may confound the diagnosis of AD or would interfere with assessment of treatment.
• Treatment with topical PDE-4 inhibitor within 2 weeks prior to randomization.
• Treatment with the following immunomodulatory medications or bleach baths within 4 weeks prior to baseline:

• Systemic immunosuppressive/immunomodulating drugs (e.g. methotrexate, cyclosporine, azathioprine, mycophenolate mofetil, JAK inhibitors).
• Systemic corticosteroid use (excludes topical, inhaled, ophthalmic, or intranasal delivery).
• 3 or more bleach baths during any week within the 4 weeks.
• Receipt of any marketed biological therapy or investigational biologic agents (including immunoglobulin, anti-IgE, or dupilumab):

• Any cell-depleting agents, including but not limited to rituximab: within 6 months prior to baseline, or until lymphocyte count returns to normal, whichever is longer.
• Other biologics (including dupilumab): within 3 months or 5 halflives, whichever is longer, prior to baseline.
• Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antifungals, or antiprotozoals within 2 weeks before the baseline visit.
• History of malignancy at any time before the baseline visit.
• History of anaphylaxis following any biological therapy.
• History of immune complex disease.
• Active or suspected endoparasitic infections.
• History of past or current tuberculosis or other mycobacterial infection.
• Established diagnosis of a primary immunodeficiency disorder.

• Minimum Eligible Age: 6 Years
• Maximum Eligible Age: 11 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

LEO Pharma

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Medical Expert

Role: STUDY_DIRECTOR

LEO Pharma

Locations

LEO Pharma Investigational Site

Brno, , Czechia

LEO Pharma Investigational Site

Prague, , Czechia

LEO Pharma Investigational Site

Reims, Ardennes, France

LEO Pharma Investigational Site

Rotterdam, , Netherlands

LEO Pharma Investigational Site

Utrecht, , Netherlands

LEO Pharma Investigational Site

Cadiz, Andalusia, Spain

LEO Pharma Investigational Site

Esplugues de Llobregat, Barcelona, Spain

LEO Pharma Investigational Site

Alicante, , Spain

LEO Pharma Investigational Site

Manchester, Greater Manchester, United Kingdom

LEO Pharma Investigational Site

London, , United Kingdom

LEO Pharma Investigational Site

Sheffield, , United Kingdom

Countries

Czechia; France; Netherlands; Spain; United Kingdom

Other Identifiers

2021-005573-12

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

U1111-1282-4394

Identifier Type: OTHER

Identifier Source: secondary_id

2024-512791-36-00

Identifier Type: CTIS

Identifier Source: secondary_id

LP0162-1335

Identifier Type: -

Identifier Source: org_study_id